SUMMARY Gastrointestinal function was assessed in six patients with rheumatoid arthritis who had developed diarrhoea on treatment with Auranofin. With the administration of Auranofin whole gut transit time decreased markedly (to 50% or less of control values) in five of six patients. The speed of passage of intestinal contents through the colon was certainly increased but attempts to assess transit through the upper gastrointestinal tract failed because the breath hydrogen method gave inconclusive results. There was no evidence of colitis and in all cases biopsy of the rectal mucosa appeared normal by light microscopy. In the five patients with rapid intestinal transit faecal weight increased more than two-fold (range +44 to +335%) although in only three cases were the changes sufficient to cause an increased frequency of bowel action. Overall the concentration of sodium in faecal water increased three-fold (mean values rose from 10.6 to 38.3 mmol/l). There were no significant changes in the concentrations of either potassium or chloride but bicarbonate was reduced. Faecal pH fell from a mean value of 7.5 (range 6.8-7.9) to a mean value of 6-4 (range 6.0-7.4). In the three patients who developed overt diarrhoea and in two others taking Auranofin the intestinal uptake of 51Cr-EDTA was increased on average three-fold and there was a similar change in the ratio of the absorption of lactulose/mannitol. The mean clearance of alpha-1-antitrypsin from the circulation into the gastrointestinal tract was doubled. These data indicate an increase in intestinal permeability. In contrast the absorption of vitamin B12 was unaffected and there was no significant change in the excretion of faecal fat although one patient developed mild steatorrhoea. Thus in a selected group of subjects with rheumatoid arthritis the administration of Auranofin caused diarrhoea in association with a reversible defect in intestinal permeability but without significant change in the absorption of nutrients.
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Auranofin, an orally absorbed gold preparation, has been used in trials of treatment for rheumatoid arthritis over the past 10 years.' Abdominal pain and diarrhoea are common side effects which limit more widespread use of the drug. These syptoms occur most often during the first few weeks of treatment and usually disappear promptly if the drug is stopped. It is important, however, to determine the mechanism by which Auranofin
In a recent study of 25 patients taking Auranofin 11 had loose stools for a week or more during the course of treatment. 13 Protein loss into the intestine was measured by the alpha-1-antitrypsin method.14 Biopsies of rectal mucosa were processed using routine histological techniques. The specimens were examined by a specialist in gastrointestinal pathology and by the principal investigator in this study (RB).
Results

CLINICAL OBSERVATIONS
Subjects remained reasonably well throughout the study except for patient 2. Initially, she was entered to a clinical trial of Auranofin at a dose of 6 mg/day. Treatment was stopped twice because of diarrhoea. The dose was then reduced to 3 mg/day. Four months after starting the treatment she developed oral ulceration which resolved after dental treatment. The patient agreed to enter the diarrhoea study and the dose of Auranofin was increased from 3 to 6 mg/day. Towards the end of the study oral ulceration recurred and this persisted until the drug was withdrawn.
During the course of the study most patients reported mild abdominal cramping after taking the morning dose of Auranofin. This led to an urge to defaecate after one to three hours. During the off Auranofin phase all patients had firm stools with a mean frequency of three to four bowel actions per five days. During the Auranofin phase of the study stool consistency changed for five out of the six patients but this led to an increased frequency of bowel action in only three subjects (with an increase in mean frequency from three to four to eight to 11 motions/five days). Stool weights were increased in five out of six patients during the test phase on Auranofin. For all six patients mean values were 155.8 g/day compared with 69.7 g/day off Auranofin (Table 2) . Stools did not contain excess mucus but tests for occult blood were mildly positive on several occasions throughout the course of the study. There was no apparent change in blood loss as a result of giving Auranofin. The rectal mucosa was macroscopically normal in all subjects at the end of treatment with Auranofin.
FAECAL ANALYSIS
In patient 4 it was not possible to undertake a comparative study because the dialysis bags disintegrated during prolonged passage through the colon during the phase off Auranofin. In the other five patients there were significant changes in the composition of stool water. Mean values for faecal sodium increased from 106 (range 4-18) to 38-3 mmol/l (range 21-53) and faecal bicarbonate fell from 14-4 (range 8-18) to 8-7 mmol/l (range 6-14).
There was no significant change in the concentrations of potassium or chloride ions (off Auranofin, The excretion of 5tCr-EDTA was increased threefold by the administration of Auranofin from a mean value of 1*4% at 12 hours to a mean value of 4.3% (Fig. 1) . There was similar increase in the excretion of lactulose over six hours (off Auranofin mean value 0-76%; on Auranofin mean value 1.26%) with no consistent change in the excretion of mannitol (a much smaller molecule which appears to be absorbed by a different route). The lactulose/ mannitol ratio increased from a mean of 0*070 to 0*169 (Fig. 1) In 1976 it was reported that Auranofin, an orally absorbed gold compound, was a well tolerated and effective anti-rheumatic drug.17 It has a complex structure -(2,3,4,6-tetra-O-acetyl-1-thio-i-Dglucopyranosato-S) (Tri-ethyl phosphine) gold -and of a dose of 6 mg only 25% is absorbed. A much lower percentage of gold is retained in the body than with the parenteral compounds. Up to 95% is excreted in faeces. '5 Rash, stomatitis, and proteinuria occur infrequently during treatment with Auranofin. On the other hand nearly half of patients taking the drug complained of abdominal cramps and occasional diarrhoea. 3 18 In the Addenbrooke's series 30 of 44 patients developed diarrhoea. Ten patients refused to take the drug either because of the severity of the diarrhoea or because of associated abdominal colic (unpublished observations).
Auranofin is only slightly soluble in water and exerts no significant osmotic effect in the lumen of the intestine. It does not cause malabsorption as assessed by conventional tests. Our data supplement those from a previous study of three patients who were shown to absorb both fat and vitamin B12 normally when taking Auranofin. Studies of the uptake of D-xylose and glucose also gave normal results.3 One cannot, however, exclude the possibility of a transient direct effect of Auranofin on transport systems across the surface membrane of the enterocyte. Experimentally Auranofin in a concentration of 100 gg/ml (0.14 mmol/l) reduces the transport of glycine, galactose, Na+ and fluid across everted preparations of rat midintestine by 40-55%.19 It has been suggested that Auranofin causes these changes by a direct effect on sodium transport and that the transfer of monosaccharides and amino acids are reduced because they are sodium dependent. At present we have no data on the concentration of Auranofin in the human intestinal lumen following a therapeutic dose. It is reasonable to suppose that the drug would be diluted in at least 100 ml of gastrointestinal secretions and thus concentrations of 100 gg/ml would be reached only transiently if at all.
Auranofin increases the rate of transit through the gastrointestinal tract as a whole. This may be due to a neurohormonal effect on gastrointestinal motility or to increased transit secondary to increased fluid in the lumen of the gut. As expected the more than two-fold increase in stool weight was associated with an increased sodium concentration in faecal water. This change occurs with most diarrhoeal illnesses irrespective of cause.6 The concentration of hyd-rogen ion in faecal water also increased and there was a fall in the concentration of bicarbonate. The absence of change in the concentration of chloride suggests that Auranofin did not have a significant effect on the chloride-bicarbonate exchange mechanism. The fall in pH may occur as the result of accumulation of volatile fatty acids generated by bacteria principally from dietary residue.6 In this study it has also been shown that Auranofin increases intestinal permeability to 51Cr-EDTA and to lactulose and causes a small but consistent increase in the intestinal clearance of ac-1-antitrypsin. These findings suggest that the drug exerts a direct effect on the absorptive membrane of the enterocyte in vivo similar to that described in rat intestine under experimental conditions.20 In vivo perfusion of rat jejunum with a physiological solution containing electrolytes, glucose, mannitol, and taurocholate together with Auranofin (0.2 mmol/l) has been shown to induce electrolyte secretion, to inhibit the secretion of glucose and to allow an increase in the uptake of mannitol. A higher concentration of Auranofin (2 mmolI1) led to similar changes in intestinal function which were associated with histological evidence of mucosal injury (shedding of cells from the tips of villi). The authors of these observations conclude that Auranofin causes diarrhoea by inducing the secretion of intestinal fluid, in association with enhanced mucosal permeability. The changes are induced by Auranofin but not by myochrysine which suggests that the carrier molecule and not the gold is responsible for the change.
Thus there are unresolved differences between the two sets of investigations in experimental animals. One postulates a defect in absorption19
whereas the other indicates increased mucosal secretion20 albeit in association with an impaired uptake of glucose. In both sets of experiments the concentration of Auranofin maintained in contact with the intestinal mucosa throughout the experiment would occur for only short periods under therapeutic conditions. It is probable that the laxative-like effect of Auranofin on gastrointestinal function is pathophysiological rather than idiosyncratic. It occurs in a high percentage of subjects; it is closely related to the time of ingestion of the drug; it usually settles promptly after discontinuing medication and it may be relieved by reducing or dividing the dose. Some patients get mild abdominal cramp without diarrhoea and in others symptoms are transient .18 This was noted in patient 4 who had stopped taking Auranofin five weeks before the study because of diarrhoea. Her bowel habit remained normal when given Auranofin for a further two weeks even though both intestinal permeability and the clearance of x-1-antitrypsin were increased.
It has been suggested that prostaglandins may be involved in the disturbance of bowel function caused by Auranofin21 It is interesting to note that nonsteroidal anti-inflammatory drugs (NSAID) which inhibit the synthesis of prostaglandins also increase intestinal permeability and occasionally have a laxative-like effect. 22 23 In this study patients were not allowed to take NSAID which might have supplemented or multiplied the effect of Auranofin. It is of course possible that the permeability effect and the development of diarrhoea are unrelated. Be that as it may we were unable to show inflammatory changes in the intestine as a result of Auranofin. It is probable that the single reported case of enterocolitis in a patient taking Auranofin is unrelated to the laxative effect of the drug.
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